Details for Patent: 12,721,817
Which drugs does patent 12,721,817 protect, and when does it expire?
Patent 12,721,817 protects DULOXETINE HYDROCHLORIDE and is included in one NDA.
Drugs Protected by US Patent 12,721,817
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Almatica | DULOXETINE HYDROCHLORIDE | duloxetine hydrochloride | CAPSULE, DELAYED REL PELLETS;ORAL | 219131-001 | Feb 27, 2026 | RX | Yes | Yes | 12,721,817 | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Almatica | DULOXETINE HYDROCHLORIDE | duloxetine hydrochloride | CAPSULE, DELAYED REL PELLETS;ORAL | 219131-002 | Feb 27, 2026 | RX | Yes | No | 12,721,817 | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Almatica | DULOXETINE HYDROCHLORIDE | duloxetine hydrochloride | CAPSULE, DELAYED REL PELLETS;ORAL | 219131-003 | Feb 27, 2026 | RX | Yes | No | 12,721,817 | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
